alexa Comparable Cellular Immune Responses in Patients with and without Antiretroviral Treatment after Immunization with HIV-1 P24, P17 and Tat Consensus Peptides (Vacc-5q) | Abstract
ISSN 2155-6113

Journal of AIDS & Clinical Research
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Comparable Cellular Immune Responses in Patients with and without Antiretroviral Treatment after Immunization with HIV-1 P24, P17 and Tat Consensus Peptides (Vacc-5q)

Anne-Marte B Kran1,3*, Andreas Lind2,3, Maja M Sommerfelt4, Ingebjørg Baksaas5, Birger Sørensen4 and Dag Kvale2,3

1Department of Microbiology, Oslo University Hospital, Oslo, Norway

2Department of Infectious Diseases, Oslo University Hospital, Norway

3Institute of Clinical Medicine, University of Oslo, Norway

4Bionor Pharma ASA, Oslo, Norway

5Mericon AS, Skien, Norway

*Corresponding Author:
Anne-Marte Bakken Kran
Ullevål Department of Microbiology
Oslo University Hospital
Ullevål, N-0407 Oslo, Norway
Tel: +47 22 11 85 04/+47 22 11 88 45
Fax: +47 22 11 88 42
E-mail: [email protected]

Received Date: February 14, 2014; Accepted Date: March 29, 2014; Published Date: April 10, 2014

Citation: Kran AMB, Lind A, Sommerfelt MM, Baksaas I, Sørensen B, et al. (2014) Comparable Cellular Immune Responses in Patients with and without Antiretroviral Treatment after Immunization with HIV-1 P24, P17 and Tat Consensus Peptides (Vacc-5q). J AIDS Clin Res 5:296. doi:10.4172/2155-6113.1000296

Copyright: © 2014 Kran AMB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Objectives: Therapeutic vaccination in chronic HIV-infection aims to attenuate disease progression by promoting new HIV-specific T cell-clones. Most clinical trials with therapeutic vaccines are conducted on patients receiving antiretroviral therapy (ART). However, studies of vaccination in untreated individuals are limited. We present the first data from a phase I/II clinical trial with a peptide-based therapeutic vaccine (Vacc-5q) consisting of five short, modified consensus peptides from p17, p24, and Tat. In addition to evaluating safety and immunogenicity of Vacc-5q, we compared responses induced in patients on effective ART with those of ART-naïve patients.

Methods: HIV-infected patients stable on ART (n=10) and treatment naive patients (n=10) received 11 intradermal injections of Vacc-5q over 26 weeks, using GM-CSF as an adjuvant. Immunogenicity was assessed both in vivo by delayed type hypersensitivity (DTH) skin tests, and in vitro by T cell activation assays. Persistence of immune responses was retested after 3.5 years.

Results: Vacc-5q was found to be immunogenic. Specific T cell-responses both in vivo and in vitro increased significantly from baseline to week 4 (p<0.01), and were still present after 3.5 years. No significant differences were observed between ART treated and ART naïve patients at any time point.

Conclusion: Vacc-5q induced potent HIV associated cellular immune responses both in ART treated and in treatment-naïve viremic patients. These responses were comparably strong in both study arms and still present after 3.5 years, indicating that suppression of plasma viral load by ART might not be essential for optimal immunization.

Keywords

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7